Having a pathologist onsite during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies performed due to an inadequate sample, according to a study presented at the American Roentgen Ray Society annual meeting.
Having a pathologist onsite during ultrasound-guided thyroid biopsies can decrease the number of repeat biopsies performed due to an inadequate sample, according to a study presented at the American Roentgen Ray Society annual meeting.
University of North Carolina researchers compared 200 biopsies performed with a pathologist onsite and 200 with no pathologist present. All other factors being equal, 13.5% of biopsies performed without a pathologist onsite needed to be repeated, compared with only 5% where a pathologist was onsite, according to the research.
An inadequate sample is one where the pathologist deems there is an insufficient amount of tissue to make a diagnosis.
“We recommend that radiologists performing large numbers of thyroid biopsies use onsite pathology as it may reduce the need for repeat biopsy by up to 60%,” said Dr. Wui K. Chong, lead author of the study and an associate professor of radiology at UNC.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.